Enviar artigo por via de e-mail The methylation status of GSTP1, APC, and RASSF1 genes in human prostate cancer samples: Comparative analysis of diagnostic informativeness of MS-HRM and hybridization on the Illumina Infinium HumanMethylation450 BeadChip
- Autores: Skorodumova L.O.1, Babalyan K.A.2, Sultanov R.2, Vasiliev A.O.3, Govorov A.V.3, Pushkar D.Y.3, Prilepskaya E.A.3, Danilenko S.A.1, Generozov E.V.1, Larin A.K.1, Kostryukova E.S.1,2, Sharova E.I.1
-
Afiliações:
- Federal Research and Clinical Center of Physical-Chemical Medicine
- Moscow Institute of Physics and Technology (State University)
- Evdokimov Moscow State Medical Stomatological University (MSMSU)
- Edição: Volume 11, Nº 2 (2017)
- Páginas: 194-201
- Seção: Article
- URL: https://journals.rcsi.science/1990-7508/article/view/197818
- DOI: https://doi.org/10.1134/S199075081702007X
- ID: 197818
Citar
Acesso aberto
Acesso está concedido
Somente assinantes
Resumo
There is a clear need in molecular markers of prostate cancer (PC) that would specify stratification of patients into risk categories and serve as additional parameters to clinical prognostic factors. Altered DNA methylation status is one of molecular processes that occur during PC development. The gene methylation status may be evaluated in laboratory diagnostics by a PCR approach known as means of methylation-sensitive high resolution melting (MS-HRM) curve analysis. This method is particularly promising due to minimal amounts of DNA required for analysis (10 ng). To date, numerous data based on the use of Infinium HumanMethylation450 BeadChip (HM450) technology have been accumulated on DNA methylation in PC samples. However, it remains unclear whether the MS-HRM results are consistent with chip hybridization data. The aim of this study was to perform the comparative analysis of the diagnostic informativeness of MS-HRM and HM450 chip hybridization methods in determination of the methylation status of three genes GSTP1, APC, and RASSF1 in samples obtained from PC patients. The study has shown that using the MS-HRM method it is possible to discriminate PC tumor samples from samples of histologically unaltered prostate tissue by analyzing the methylation status of each gene. Analysis of chip hybridization data confirmed the results obtained by MS-HRM. Differences between tumor tissue and histologically intact tissue obtained from each PC patient in the methylation levels of GSTP1, APC, and RASSF1, determined by MS-HRM or chip hybridization were consistent with each other. Thus, the assessment of the methylation level of gene GSTP1, APC, and RASSF1 using MS-HRM can become the basis for the development of a laboratory test, the specifying diagnosis of prostate cancer.
Palavras-chave
Sobre autores
L. Skorodumova
Federal Research and Clinical Center of Physical-Chemical Medicine
Autor responsável pela correspondência
Email: l.skorodumova@rcpcm.org
Rússia, ul. Malaya Pirogovskaya 1a, Moscow, 119435
K. Babalyan
Moscow Institute of Physics and Technology (State University)
Email: l.skorodumova@rcpcm.org
Rússia, Dolgoprudniy, Moscow region
R. Sultanov
Moscow Institute of Physics and Technology (State University)
Email: l.skorodumova@rcpcm.org
Rússia, Dolgoprudniy, Moscow region
A. Vasiliev
Evdokimov Moscow State Medical Stomatological University (MSMSU)
Email: l.skorodumova@rcpcm.org
Rússia, Moscow
A. Govorov
Evdokimov Moscow State Medical Stomatological University (MSMSU)
Email: l.skorodumova@rcpcm.org
Rússia, Moscow
D. Pushkar
Evdokimov Moscow State Medical Stomatological University (MSMSU)
Email: l.skorodumova@rcpcm.org
Rússia, Moscow
E. Prilepskaya
Evdokimov Moscow State Medical Stomatological University (MSMSU)
Email: l.skorodumova@rcpcm.org
Rússia, Moscow
S. Danilenko
Federal Research and Clinical Center of Physical-Chemical Medicine
Email: l.skorodumova@rcpcm.org
Rússia, ul. Malaya Pirogovskaya 1a, Moscow, 119435
E. Generozov
Federal Research and Clinical Center of Physical-Chemical Medicine
Email: l.skorodumova@rcpcm.org
Rússia, ul. Malaya Pirogovskaya 1a, Moscow, 119435
A. Larin
Federal Research and Clinical Center of Physical-Chemical Medicine
Email: l.skorodumova@rcpcm.org
Rússia, ul. Malaya Pirogovskaya 1a, Moscow, 119435
E. Kostryukova
Federal Research and Clinical Center of Physical-Chemical Medicine; Moscow Institute of Physics and Technology (State University)
Email: l.skorodumova@rcpcm.org
Rússia, ul. Malaya Pirogovskaya 1a, Moscow, 119435; Dolgoprudniy, Moscow region
E. Sharova
Federal Research and Clinical Center of Physical-Chemical Medicine
Email: l.skorodumova@rcpcm.org
Rússia, ul. Malaya Pirogovskaya 1a, Moscow, 119435
Arquivos suplementares
